China has approved Eli Lilly’s once-daily weight-loss tablet orforglipron, making the American drugmaker the first company to win clearance for a weight-management pill of this type in the country. The decision was announced by China’s medicines regulator on Thursday, 12 November 2026.
Until now, Chinese patients seeking drug treatment for obesity could only use injections. Orforglipron changes that. It belongs to the GLP-1 family of medicines, which copy a gut hormone to reduce appetite and help control blood sugar, but unlike the injections it is taken as a small tablet once a day. The drug is a small-molecule, non-peptide version of the treatment, and it is already sold in the United States under the brand name Foundayo.
A lead over Novo Nordisk
The approval hands Lilly an early advantage over its Danish rival Novo Nordisk in the world’s second-largest market for medicines. Novo has also asked Chinese regulators to approve an oral version of its Wegovy injection, and its application was accepted for review in August 2026, but it has not yet been cleared. Other companies, including Jiangsu Hengrui Pharmaceuticals and Huadong Medicine, are also working on rival weight-loss pills.
Orforglipron will compete with a crowded field of injections already on sale in China, including Lilly’s own once-weekly treatment and products from Novo, Pfizer and the local maker Innovent Biologics. A tablet could appeal to patients who dislike needles, and doctors say easier treatment could bring in people who have so far stayed away from weight-loss drugs altogether.
A fast-growing market
The commercial stakes are large. China’s National Health Commission has projected that more than 65 per cent of the population could be overweight or obese by 2030. Yang Huang, who leads China healthcare research at J.P. Morgan, has estimated that sales of GLP-1 weight-management drugs in China could grow from about 3 to 4 billion yuan to 30 billion yuan over five to seven years.
Lilly has been preparing for that growth. In March 2026 the company said it would invest 3 billion dollars in China over ten years, with some of the money going towards expanding production capacity for orforglipron and building local manufacturing for oral medicines. The company filed its Chinese marketing application for the drug in late 2025.
What patients will actually pay, and when the tablet will reach pharmacies, is still unclear. Lilly did not immediately respond to questions about pricing or the launch date in China. In the United States, oral weight-loss treatments already account for about a third of obesity prescriptions since Novo’s Wegovy pill reached patients in January this year, a sign of how quickly tablets are catching on.